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Abstract
Background: The aim of this meta-analysis is to evaluate the impact of transthoracic resection on long-term survival of
patients with GEJ cancer and to compare the postoperative morbidity and mortality of patients undergoing transthoracic
resection with those of patients who were not undergoing transthoracic resection.
Method: Searches of electronic databases identifying studies from Medline, Cochrane Library trials register, and WHO Trial
Registration etc were performed. Outcome measures were survival, postoperative morbidity and mortality, and operation
related events.
Results: Twelve studies (including 5 RCTs and 7 non-RCTs) comprising 1105 patients were included in this meta-analysis,
with 591 patients assigned treatment with transthoracic resection. Transthoracic resection did not increase the 5-y overall
survival rate for RCTs and non-RCTs (HR=1.01, 95% CI 0.80- 1.29 and HR=0.89, 95% CI 0.70- 1.14, respectively). Stratified by
the Siewert classification, our result showed no obvious differences were observed between the group with transthoracic
resection and group without transthoracic resection (P.0.05). The postoperative morbidity (RR=0.69, 95% CI 0.48- 1.00 and
OR=0.55, 95% CI 0.25- 1.22) and mortality (RD= 20.03, 95% CI 20.06- 0.00 and RD=0.00, 95% CI 20.05- 0.05) of RCTs and
non-RCTs did not suggest any significant differences between the two groups. Hospital stay was long with thransthoracic
resection (WMD= 25.80, 95% CI 210.38- 21.23) but did not seem to differ in number of harvested lymph nodes, operation
time, blood loss, numbers of patients needing transfusion, and reoperation rate. The results of sensitivity analyses were
similar to the primary analyses.
Conclusions: There were no significant differences of survival rate and postoperative morbidity and mortality between
transthoracic resection group and non-transthoracic resection group. Both surgical approaches are acceptable, and that one
offers no clear advantage over the other. However, the results should be interpreted cautiously since the qualities of
included studies were suboptimal.
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Introduction
Gastroesophageal junction (GEJ) cancer has been gradually
considered as an entity separate from both esophageal cancer and
gastric cancer [1]. Although a decline in incidence of gastric
carcinoma, there has been a tendency of proximal migration of
carcinoma in Western countries [2–4]. A kind of classification
proposed by Siewert & Stein, which includes three types, was
widely accepted for GEJ cancer [5]. According to the classifica-
tion, type 1 is defined as tumors whose centers are located 1 to
5 cm above the gastroesophageal junction (distal esophageal
adenocarcinoma); type 2, adenocarcinoma with its epicenter
located between 1 cm proximal and 2 cm distal of the GEJ, is
defined as a true cardia carcinoma; and the center of the type 3
tumor lies 2 to 5 cm distal to the GEJ (subcardial gastric
carcinoma) [5].
Surgery is the mainstay treatment although the prognosis is
poor. Controversies, especially on operation route, still exist. The
debate on the question whether transthoracic (TT) resection or
non- transthoracic resection is better for GEJ cancer remains
continuing. Transthoracic resection was advocated with intent to
prolong the survival, because mediastinal lymph nodes could be
observed and dissected under the direct vision and a safe surgical
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transthoracic resection, such as transhiatal resection or transab-
dominal resection, was recommended since it could decrease the
respiratory complications related to transthoracic resection and
the damage caused by the anastomotic leakage [9–14]. In
addition, positive metastasis of mediastinal lymph nodes indicated
a poor prognosis even though the dissection was complete [9,15].
Although some randomized controlled trials (RCTs) had not
showed the superiority of transthoracic resection to non-transtho-
racic resection for Siewert type 1 and 2 GEJ cancers, transthoracic
resection did show better trend for survival [12,14,16]. Neverthe-
less, Sasako M et al demonstrated the opposite results for type 2
and 3 GEJ cancers [15]. And Goldfaden et al also claimed
transhiatal esophagectomy performed a better survival advantage
for type 1 patients in spite of no statistical difference [17]. For
safety, several studies have shown a lower incidence of complica-
tions with non-transthoracic resection [13–15]. However, some
authors argued that the transthoracic resection technique do not
increase the morbidity and mortality [11,12,18].
So there is still uncertainty in aspects of survival and safety
between transthoracic resection and non-transthoracic resection
for GEJ cancers. The aim of this meta-analysis is to evaluate the
impact of transthoracic resection on long-term survival of GEJ
cancer and to compare the postoperative morbidity and mortality
of patients undergoing transthoracic resection with those of
patients who were not undergoing transthoracic resection.
Methods
In order to guarantee the quality, this meta-analysis was
conducted in line with recommendations from the Cochrane
Collaboration and the Quality of Reporting Meta-Analyses
(QUOROM) statement [19].
Search Strategy and Study Selection
We searched electronic databases of PubMed. The further
websites and conference proceedings were searched, including
Cochrane Central Register of Controlled Trials, National Cancer
Institute, European Organization for Research and Treatment of
Cancer, Southwest Oncology Group, ClinicalTrials.gov, Ameri-
can Society of Clinical Oncology, and European Society of
medical Oncology. Moreover, the reference lists from relevant
articles were screened for eligibility. The eligible unpublished grey
papers which were prevented from publication because of conflict
of interests were considered to be included also, if known to Prof.
Chen ZX and Prof. Chen JP.
The search strategy of Medline was as follows and was also
applied to other databases: [((‘‘Gastroesophageal Junction’’[Mesh]
AND ‘‘Carcinoma’’[Mesh]) OR (‘‘Stomach Neoplasms’’[Mesh]
AND ‘‘Carcinoma’’[Mesh]) OR (‘‘Cardia’’[Mesh] AND ‘‘Carci-
noma’’[Mesh]) OR (‘‘Carcinoma’’[Mesh] AND ‘‘Esophageal
Neoplasms’’[Mesh]) ) OR ((((((((gastroesophageal junction) OR
gastroesophageal junction) OR ogastroesophageal junction) OR
distal esophageal) OR lower third esophageal) OR cardia) OR
subcardial) OR siewert)] AND (((((transhiatal [Title/Abstract]) OR
transabdominal[Title/Abstract]) OR transthoracic[Title/Ab-
stract]) OR thoracoabdominal[Title/Abstract]) OR abdomi-
nothoracic[Title/Abstract]). The electronic search was up to
November, 2011 with no limitations on publication date and
language.
Inclusion and Exclusion Criteria
Any kinds of articles including RCTs, controlled clinical trials,
Cohort studies, case-control studies, and case series which
compared the effectiveness or safety of transthoracic resection to
those of non-transthoracic resection were eligible.
The inclusion criteria were as follows: Tumor should locate at
distal esophagus, cardia or subcardia as Siewert classification. The
patients had to have histological proven adenocarcinoma as
reported in the texts. The patients treated with chemotherapy,
immunotherapy etc perioperatively were included. The patients
received thoracotomy or non-thoracotomy. There was no
limitation of age, gender, and race. Curative & palliative
operations were included. One or more outcome measures should
be extracted. And the exclusion criteria contained: Recruited
patients with carcinoma at other location of stomach or esophagus,
such as gastric antrum or middle/upper third of esophagus or EGJ
cancer could not be stratied for analysis were excluded. Patients
with metachronous or synchronous double cancer were excluded.
Patients with other significant comorbidities, such as benign
diseases or other kinds of tumors (lymphoma etc) were excluded.
Patients whose operations were performed according to the
location of tumors were excluded. Trials possessing uncertainty
or important inequality of characteristics on baselines between
groups were excluded.
Selection, Assessment, and Data Extraction
In order to select studies for further assessment, two indepen-
dent reviewers screened the title, abstract section, and keywords of
every record retrieved. Full articles were assessed if the given
information suggested that the study conformed to our criteria
described above.
Any disagreements in quality assessment and data collection
were discussed and solved by a third reviewer (Hu JK and Zhang
B) as the referee.
Data was extracted independently by two reviewers. Details of
study sample (number of each arm, study population character-
istics, and matching items), interventions (the detail of operation,
as well as details of other treatment, such as adjuvant chemother-
apy etc.) and outcomes (5-year overall survival rate, postoperative
mortality and morbidity, and operation related events) were
extracted. Additionally, first author, the year of study, study
design, the number and reason of withdrawals, dropouts and their
characteristics were extracted.
Seven items relevant to the quality appraisal were used for
assessing [20]: 1) whether the method of allocation was truly
random; 2) whether there was proper concealment of allocation; 3)
whether there was equality between two groups at baseline in terms
of prognostic features; 4) whether the eligibility criteria were
described; 5) whether blindness of the outcome assessors was
performed; 6) whether loss to follow-up in each treatment arm
was demonstrated, and 7) whether intention-to-treat analysis was
considered. Studies with seven or six ‘yes’ was required for a trial to
be rated as high quality, while five or four ‘yes’ for fair quality and
three or fewer ‘yes’ for low quality [20].
The qualities of non-randomized studies were assessed by using
the Newcastle-Ottawa Scale (NOS) with some modifications to
match the needs of this study [21]. The quality of the studies was
evaluated by examining patient selection methods, comparability
of the study groups, and assessment of outcomes. Studies achieving
six or more scores were considered to be of relative high quality.
Outcomes of Interest and Definitions
The primary outcome measures were 5-year overall survival
rate, overall hospital or postoperative 30 day mortality, and overall
morbidity rate, while the secondary outcome measure were
specific operation related events, including number of harvested
lymph nodes, operation time, intra-operative blood loss, number
Transthoracic Resection for GEJ Cancers
PLoS ONE | www.plosone.org 2 June 2007 | Volume 7 | Issue 6 | e37698of patients needing transfusion, length of hospital stay, and
reoperation rate. One or more outcome measures were required in
the included trials, or they were excluded.
Statistical Analysis
For dichotomous data, relative risks (RR) for RCTs and odds
ratios (OR) for non-RCTs which were weighted estimates of
treatment effect across trials were calculated. If the RR or OR
could not be estimated because of a low incidence event in either
group, the risk difference (RD) was calculated instead [22].
Continuous data was calculated as weighted mean differences
(WMD) with 95% confidence intervals. The analyses were
conducted using RevMan 5.0 provided by the Cochrane
Collaboration [23]. The P value,0.05 was considered as
statistically significant. The overall survival rates were calculated
as hazard ratios (HR). If only survival curves were reported, the
overall 5-year survival rates were extracted and converted from the
figures as accurately as possible [24]. When the trials had reported
medians and ranges instead of means and standard deviations, the
means and standard deviations (SD) were calculated according to
Hozo SP et al [25]. If the data could not be extracted for meta-
analysis, we presented the results in a descriptive and qualitative
manner [26]. Heterogeneities of treatment effect between trials
were tested using a Chi-squared statistic with significance being set
at P,0.10, and I-square was used to estimate total variation across
studies that was due to heterogeneity rather than chance (,25%
was considered as low level heterogeneity, 25% to 50% as
moderate level, and higher than 50% as high level) [27]. If
heterogeneities existed, one of the following techniques was
undertaken to attempt to explain: 1.Random effect model for
meta-analyses was considered; 2. Sub-group analyses; 3. Sensitivity
analyses were considered. The subgroup analyses were considered
to be performed stratified by the Siewert classification. Some
common specific postoperative complications were also analyzed
in the subgoup analysis. Sensitivity analyses were performed
according to the following aspects: refer to high quality trials only
to avoid the misleading caused by poor quality studies [28],
combine RCT and non-RCT studies, use studies with direct
statistic method only, utilize studies matched stage only, or apply
the final survival results of JCOG9502 trial instead of results of the
first interim analysis. Tests for funnel plot asymmetry were
planned to be used only when there are at least ten studies
included in each meta-analysis [29].
Results
Study Selection
There were 875 studies identified in total using the predefined
search strategy (including 9 RCTs and 866 non-RCTs). Checking
the references of retrieved studies did not provide any further
studies for evaluation. Subsequently, selection was performed
according to the inclusion/exclusion criteria set out in the
Methods section. Through browsing the retrieved titles and their
Figure 1. Flow chart for selection of studies. The flowchart of selecting procedure and the exclusive reason of studies are summarized.
doi:10.1371/journal.pone.0037698.g001
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followed by exclusion of a further 59 articles at the secondary
selection step, which involved reading the full texts of potentially
eligible studies. The flowchart of selecting procedure and the
exclusive reason of studies are summarized in Figure 1.
Twelve studies (including 5 RCTs and 7 non-RCTs) meeting
the inclusion criteria were chosen [12,14–17,30–36]. No grey
papers were found. Two non-RCT studies with imbalanced
baseline of comorbidity were included since postoperative
morbidity and mortality were not their outcomes and cancer-
related deaths were compared [32,34]. The publication years of
these studies ranged from 1986 to 2010. Because some publica-
tions reported on the same trial and the same patient groups
differed only in analyzed parameters, only 9 studies were
applicable [14–16,30]. The characteristics and quality assessments
of included trials were listed in Table 1 and 2.
A total of 1105 patients were available for analysis, with 591
patients treated with transthoracic resection (considered as control
group in this meta-analysis).
Survival
The meta-analysis of RCTs and non-RCTs showed there were
no significant survival benefits for the group with transthoracic
resection (HR=1.01, P=0.92 and HR=0.89, P=0.35 respec-
tively). However, the pooled result of non-RCTs proned to favor
the group with transthoracic resection (HR=0.89, 95% CI: 0.70-
1.14), which could not be observed from the result of RCTs
(Table 3, Figure 2). As the Siewert classification of GEJ cancer has
a major effect on the choice of operation procedure [37], we
performed the subgroup analysis stratified by the Siewert
classification.
In the subgroup analysis, we also could find, for type 1 GEJ
cancer, transthoracic resection could not facilitate survival
compared with non-transthoracic resection from the results of
RCTs and non-RCTs (Table 3, Figure 2). The HRs of 5-year
overall survival rates for RCT and non-RCT were 0.78 and 1.64
respectively. Because type 2 cancers are considered more similar to
type 3 cancers [37], we combined these two types to analyze. Our
result showed no obvious differences were observed between the
group with transthoracic resection and group without transtho-
racic resection for type 2 and 3 GEJ cancers (Table 3, Figure 2).
For those studies which were not included in the meta-analysis,
we had listed their results as follows:
The JCOG9502 reported the final survival result (15 year)
which showed the hazard ratio was 1.36 (95%CI: 0.94- 1.99) in
favor of non-transthoracic resection in spite of insignificant
difference (P=0.95) [30].
One RCT reported the median survival times were 18
(transhiatal) and 13.5 (transthoracic) months respectively with no
significant difference [12].
One non-RCT showed the 5-y survival rates were 12% and
16% for transhiatal and transthoracic groups respectively (P.0.05)
[35].
Safety
Both meta-analyses of RCTs and non-RCTs showed that
transthoracic resection did not significantly influence 30 day
mortality (RD=20.03, 95% CI: 20.06- 0.00, P=0.09 and
RD=0.00, 95% CI: 20.05- 0.05, P=0.87 respectively) (Table 3,
Figure 3). Transthoracic resection was associated with a higher
overall postoperative morbidity than non-transthoracic resection
from the results of RCTs and non-RCTs (RR=0.69, 95% CI:
0.48- 1.00, P=0.05 and OR=0.55, 95% CI: 0.25- 1.22, P=0.14
respectively), but these differences were not statistical significant
(Table 3, Figure 3).
For those studies which were not included in the meta-analysis,
the morbidity of one RCT did not show any significant differences
between transthoracic and transhiatal group [12]. Another RCT
and non-RCT reported there were no significances between
transthoracic and transhiatal group on postoperative morbidities,
except pulmonary complication [14,33].
Furthermore, subgroup analyses were performed for some
common specific postoperative complications. These analyses
showed that the incidences of complications, such as anastomotic
leakage, wound infection, cardiovascular complications, and
hoarseness were not significantly different between patients treated
with transthrocotomy and those without transthrocotomy
(P.0.05). Even with respect to pulmonary complications, the
incidences were not significant different between the two groups.
Also, the numbers of patients requiring mechanical ventilation and
durations of intubation postoperatively did not differ statistically
between the two groups (P.0.05). Patients undergoing transthro-
cotomy seemed to experience more chylous leakage and longer
ICU stay than patients without transthrocotomy (P,0.05)
(Table 4).
Operation Related Events
Hospital stay was long with thransthoracic resection
(WMD=25.80, 95% CI 210.38- 21.23) but did not seem to
differ in number of harvested lymph nodes, operation time, blood
loss, numbers of patients needing transfusion, and reoperation rate
(Table 5). Data of other trials without extractable information for
meta-analyses had been summarized in Table 6.
Table 2. The quality of included randomized trials.
Study Truly random
Concealed
allocation
Baseline
features
Eligibility
criteria
Blinding
assessment
Loss to
follow-up
Intension
to treat
Study
quality
Chu KM, 1997 [12] Unclear Unclear Yes No Unclear No Yes
a Poor
JCOG 9502, 2006 [15] Yes Unclear Yes Yes No Yes Yes Fair
Hulscher JB, 2002 [14]/Omloo JMT, 2007 [16] Yes Unclear Yes Yes Unclear Yes
b Yes
c Fair
aAll patients underwent the planned procedure.
bAll patients have completed the follow up.
cThe whole patients were analyzed by an intention to treat analysis. However, per protocol analysis was applied when the patients were stratified by the location of
tumors.
doi:10.1371/journal.pone.0037698.t002
Transthoracic Resection for GEJ Cancers
PLoS ONE | www.plosone.org 5 June 2007 | Volume 7 | Issue 6 | e37698Sensitivity Analysis
When high-quality studies, studies with direct statistic method,
studies matched for stage or the final survival results of JCOG9502
considered were re-performed for meta-analyses in sensitivity
analyses, the results were shown in Table 7. No changes of
outcomes were observed in terms of the 5-y overall survival rate,
postoperative morbidity and mortality, compared to the primary
results. When RCT and non-RCT studies were combined, there
was a significant increase in postoperative morbidity with
thransthoracic resection (OR=0.55, 95% CI: 0.31- 0.99,
P=0.04). This contrasts with the lack of evidence of difference
in 5-year overall survival and 30 day mortality (Table 7).
Discussion
The incidence of GEJ cancers has been increased [2–4].
Surgery is still considered as the potential curative treatment.
Proximal margin length and lymph node involvement are
Figure 2. Forest plot of 5-year overall survival rates for RCTs and non-RCTs. a: RCTs; b: non-RCTs. The 95% confidence interval (CI) for the
hazard ratio for each study is represented by a horizontal line and the point estimate is represented by a square. The size of the square corresponds
to the weight of the study in the meta-analysis. The 95% CI for pooled estimates is represented by a diamond. Data for a fixed-effects model are
shown as there was no statistical heterogeneity. df=degrees of freedom; I
2=percentage of the total variation across studies due to heterogeneity;
IV=Inverse Variance; SE=standard error; Z=test of overall treatment effect.
doi:10.1371/journal.pone.0037698.g002
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Transthoracic Resection for GEJ Cancers
PLoS ONE | www.plosone.org 7 June 2007 | Volume 7 | Issue 6 | e37698independent prognostic factors for GEJ cancers [16,38]. So,
transthoracic resection permitting the safe margin and a more
clearance of involved nodes is proposed to benefit the survival rate
of patietns with GEJ cancer. However, the results did not suggest
better survival sometimes [15,17,33]. Furthermore, non-transtho-
racic resection theoretically minimizes respiratory complications,
decreases risk of anastomotic leakage, reduces the incidence of
postoperative symptoms associated to gastroesophageal reflux, and
avoids a painful incision of transthoracic resection [33]. Still, some
authors reported that the transthoracic resection technique did not
increase the morbidity and mortality [11,12,18]. So, there is still
discrepancy on which one is the best approach.
Figure 3. Forest plot of mortality and morbidity. a: mortality; b: morbidity. The 95% confidence interval (CI) for the risk difference, risk ratio
or odds ratio for each study is represented by a horizontal line and the point estimate is represented by a square. The size of the square corresponds
to the weight of the study in the meta-analysis. The 95% CI for pooled estimates is represented by a diamond. Data for a fixed-effects model are
shown as there was no statistical heterogeneity. Data for a random-effects model are shown as there was statistical heterogeneity. df=degrees of
freedom; MH=Mantel-Haenszel test; I
2=percentage of the total variation across studies due to heterogeneity; Z=test of overall treatment effect.
doi:10.1371/journal.pone.0037698.g003
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PLoS ONE | www.plosone.org 8 June 2007 | Volume 7 | Issue 6 | e37698With respect to the 5-year overall survival rate, our results failed
to suggest transthoracic resection could bring more benefit to
the patients with GEJ cancers, which was in accordance with the
recent published results [39]. To avoid the bias caused by the
Siewert classification, we performed the subgroup analysis. When
stratified by the Siewert classification, transthoracic resection,
which even though was proved to not increase the survival rates of
patients with type 1 cancers, also showed the potential survival
benefit from the results of RCTs (HR=0.78, 95% CI: 0.45- 1.36).
Because type 1 cancers tend to have more positive metastasis
lymph nodes locating at the middle or upper mediastinum [15,40],
the potential more clearance of involved nodes of transthoracic
resection for type 1 cancer patients strengthened the survival
advantage [9,15,16,41]. And for type 2 and 3 cancers, our results
also showed no obvious differences were observed between the
groups with transthoracic resection and without transthoracic
resection for survival. However, the result of RCTs has showed
possible survival advantage for the group without transthoracic
resection (HR=1.21, 95% CI: 0.89- 1.63). This may derive from
the relatively skeptical quality and less scientific authority of non-
RCTs, although we indeed carefully select some non-RCTs with
good balanced baseline characteristics for meta-analysis. And also
may because that type 2 or 3 tumors were more commonly
presented as undifferentiated and less intestinal growth pattern,
greater depth of serosa invasion, higher lymph node burden, more
frequent advanced stages, and lower R0 resection rates [37], the
effect of non-transthoracic resection was a little diminished from
the result of non-RCTs. Furthermore, the power of outcomes was
restricted by the limited number of included studies and the
relative small sample size. Nonetheless, the overall survival effects
were not impacted by transthoracic resection and the authors
believed the results of survival presented in this meta-analysis
could be referred to with caution, after all. In the sensitivity
analysis, no significant differences could be detected in 5-year
overall survival rates between non-transthoracic resection group
and transthoracic resection group.
Regarding to the safety, the present meta-analysis showed
transthoracic resection did not significantly influence mortality
and morbidity. However, there was a marginal benefit of
morbidity for non-transthoracic resection (RR=0.69, 95% CI:
0.48- 1.00, P=0.05 and OR=0.55, 95% CI: 0.25- 1.22, P=0.14
respectively). Although some authors reported there were no
significant differences of pulmonary complications between
transthoracic resection and non-transthoracic resection [11–
13,18], more pulmonary complications were observed following
transthoracic resection [14,15,39,42]. Furthermore, transthoracic
resections can result in a transient deterioration of pulmonary
function during one-lung ventilation in the left-lateral position
compared with non-transthoracic resection approach, although
this might be partly compensated for during the intervention [18].
However, our subgroup analysis stratified by specific postoperative
complications demonstrated the incidences of pulmonary compl-
cations were not significant different between the two groups. Also,
the numbers of patients requiring mechanical ventilation and
durations of intubation postoperatively did not differ statistically
between the two groups. Nevertheless, the relative higher
heterogeneity might compromise the validity of the results. And
we should interpret cautiously. There seemed to be a higher
incidence of chylous leakage and longer ICU stay in patients
undergoing transthrocotomy than patients without transthrocot-
omy. However, regarding these respects, the included analyzable
trials were too few (only 1 for each). It has been suggested that
anastomosis at different locations may be associated with different
incidences of anastomotic leakage [43]. However, our results have
showed there was no significant difference for incidences of
anastomotic leakage between transthoracic anastomosis and non-
transthoracic anastomosis. Other analyses failed to show any
significant differences on the incidences of complications, such as
wound infection, cardiovascular complications, and hoarseness,
between patients treated with transthrocotomy and those without
transthrocotomy. These results were not supported by study of
Boshier PR et al [39], which demonstrated that transthoracic
group had significant higher incidences of respiratory complica-
tions, wound infections, and early postoperative mortality, whereas
anastomotic leak and recurrent laryngeal nerve palsy rate were
significantly more in the transhiatal group.
At the same time, with respect to the operation related events,
transthoracic resection had significant differences from non-
transthoracic resection in length of hospital stay, and was apt to
more blood loss and longer operation time despite of no statistical
Table 4. Pooled estimates of common specific postoperative complications.
Number of
studies
Without
TT n/N
With TT
n/N OR/WMD/RD [95% CI]
P-value for
effect size I square
P-value for
heterogeneity
Effect
model
Anastomotic leakage 7 53/454 47/605 0.93 [0.59, 1.45]
c 0.74 0 0.60 Fixed
Chylous leakage 1 2/106 11/114 0.18 [0.04, 0.83]
c 0.03 – Not applicable Fixed
Wound infection 4 10/202 18/460 20.02 [20.06, 0.02]
d 0.36 19% 0.29 Fixed
Length of ICU stay (day) 1 106
a 114
a 24.00 [26.70, 21.30]
b 0.004 – Not applicable Fixed
Cardiac complications 5 33/265 89/484 0.69 [0.43, 1.10]
c 0.12 0 0.89 Fixed
Pulmonary complications 8 75/474 129/624 0.62 [0.27, 1.43]
c 0.26 70% 0.001 Random
Hoarseness 4 27/218 28/200 0.02 [20.10, 0.14]
d 0.78 70% 0.02 Random
Mechanical ventilation
required
2 7/102 16/104 0.41 [0.16, 1.03]
c 0.06 0 0.49 Fixed
Duration of intubation 2 138
a 130
a 1.26 [23.43, 5.94]
b 0.60 81% 0.02 Random
Abbreviations: TT: Transthoracic resection; OR: Odds ratios; WMD: Weighted mean difference; RD: Risk difference.
athe summed number of patients in each group.
bWMD.
cOR.
dRD.
doi:10.1371/journal.pone.0037698.t004
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PLoS ONE | www.plosone.org 9 June 2007 | Volume 7 | Issue 6 | e37698differences. The operation time may be expensed in repositioning
and redraping the patient, and in opening and closing a
thoracotomy [12,33], which did not appear to have an adverse
effect on outcome. However, the prolonged operating time might
aggravate the burden of patients with limited cardiopulmonary
reserve [12]. And the hospital stay may be associated with the
potential increased respiratory complications as well as the
increased ventilation time, ICU stay, and tracheotomy caused by
the respiratory complications after transthoracic resection
[14,15,39]. So, transthoracic resection should be applied cautious-
ly for patients with impaired cardiopulmonary function in the
practice.
Also, there are some limitations on this meta-analysis. First, the
included researches for analyzing were limited. Second, some data
was obtained through indirect methods, such as hazard ratio from
the survival curve and mean from median.
One of the major limitations of the study is the relatively high
level of heterogeneity of the data, especially in the pooled analysis
of operation related events. This arised because the more extensive
technique of thoracotomy was preferred in treatment of Siewert
type 1 tumors because they tended to have more metastasis in the
lymph nodes of the middle or upper mediastinum than do type 2
tumors [44], and also selected for tumors with esophageal invasion
of greater than 4 cm since a safe proximal margin was easily
obtained [9,15], however was avoided for older or patients with
impaired cardiopulmonary function, although the basline charac-
teristics of patients in both groups of the included studies were
comparable. In addition, the included studies reported similar
long-term survival rates with actually different resection techniques
of thoracotomy may cause the heterogeneity of the data. The
majority of type I tumors were histologically intestinal tumor
growth pattern, while type II and III tumors were more commonly
undifferentiated tumors and had worse prognosis [45]. Further-
more, early tumors (pT1) and the pN0 category were significantly
more common in patients with type I tumors than in those with
type II or III tumors [45]. Compared with patients with type III
tumors, pN0 and pM0 categories were more common in patients
with type I and II tumors [45]. This resulted in higher R0
resection rates in patients with type I and II tumors than in
patients with type III tumors. These might be another source of
heterogeneity. In spite of the limitations of this meta-analysis, by
developing a detailed protocol before initiating the study,
performing a cautious search for published studies, using objective
methods for study selection, data extraction and analysis, and
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Table 6. Summary of data of trials without extractable
information for Meta-analyses.
Without
TT N
With
TT N
Without
TT Median
With
TT
Median
P-
value
Operation time (min)
Omloo JMT, 2007
16 106 114 210 360 ,0.001
Blood loss (ml)
Omloo JMT, 2007
16 106 114 1000 1900 ,0.001
Length of hospital stay (day)
Stark SP, 1996
80 32 16 15 14 NS
Moon MR, 1992
82 63 24 18 18 NS
Abbreviations: TT: Transthoracic resection; NS: No significant.
doi:10.1371/journal.pone.0037698.t006
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PLoS ONE | www.plosone.org 11 June 2007 | Volume 7 | Issue 6 | e37698performing the subgroup analyses and sensitivity analyses, we have
minimized the probability of bias as far as possible.
In conclusion, there were no significant differences of survival
rate, postoperative morbidity and mortality between transthoracic
resection group and non-transthoracic resection group. Both
surgical approaches are acceptable, and that one offers no clear
advantage over the other. However, the results should be
interpreted cautiously since the qualities of included studies were
suboptimal.
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